Nuvalent Toekomstige groei

Future criteriumcontroles 2/6

Nuvalent zal naar verwachting groeien in winst en omzet met respectievelijk 4.5% en 68.2% per jaar. De winst per aandeel zal naar verwachting groeien met 7.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -36.3% zijn.

Belangrijke informatie

4.5%

Groei van de winst

7.2%

Groei van de winst per aandeel

Biotechs winstgroei	28.5%
Inkomstengroei	68.2%
Toekomstig rendement op eigen vermogen	-36.3%
Dekking van analisten	Good
Laatst bijgewerkt	20 Nov 2024

Recente toekomstige groei-updates

Recent updates

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Apr 22

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Feb 26

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Jan 07

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Sep 23

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Jun 10

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Feb 24

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Sep 13

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Aug 10

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

May 28

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Oct 29

Winst- en omzetgroeiprognoses

NasdaqGS:NUVL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	34	-347	-278	-409	10
12/31/2025	8	-314	-262	-261	10
12/31/2024	N/A	-257	-223	-211	10
9/30/2024	N/A	-224	-153	-153	N/A
6/30/2024	N/A	-174	-130	-130	N/A
3/31/2024	N/A	-146	-111	-111	N/A
12/31/2023	N/A	-126	-100	-100	N/A
9/30/2023	N/A	-114	-87	-87	N/A
6/30/2023	N/A	-100	-83	-83	N/A
3/31/2023	N/A	-89	-76	-76	N/A
12/31/2022	N/A	-82	-65	-65	N/A
9/30/2022	N/A	-73	-60	-60	N/A
6/30/2022	N/A	-66	-53	-53	N/A
3/31/2022	N/A	-57	-48	-48	N/A
12/31/2021	N/A	-46	-40	-40	N/A
9/30/2021	N/A	-36	-32	-32	N/A
6/30/2021	N/A	-28	-25	-25	N/A
3/31/2021	N/A	-27	-18	-18	N/A
12/31/2020	N/A	-15	-15	-15	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat NUVL de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat NUVL de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat NUVL de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van NUVL ( 68.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van NUVL ( 68.2% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat NUVL binnen 3 jaar verliesgevend zal zijn.

Nuvalent Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 8.1% to US$111

Price target increased by 10% to US$102

Price target increased by 8.6% to US$92.13

Price target increased by 7.4% to US$84.83

Price target increased by 11% to US$59.14

Price target increased by 8.7% to US$50.83

Recent updates

CEO, President & Director exercised options and sold US$1.6m worth of stock

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Nuvalent Appoints Alice T. Shaw to its Scientific Advisory Board

CFO & Treasurer exercised options and sold US$613k worth of stock

CEO, President & Director notifies of intention to sell stock

CFO & Treasurer notifies of intention to sell stock

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Nuvalent, Inc. has completed a Follow-on Equity Offering in the amount of $500 million.

Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation

Nuvalent, Inc. has completed a Follow-on Equity Offering in the amount of $500 million.

Price target increased by 8.1% to US$111

Nuvalent, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Nuvalent, Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of Alk-Selective Inhibitor Nvl-655

CFO & Treasurer exercised options and sold US$564k worth of stock

New major risk - Revenue and earnings growth

Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business

CFO & Treasurer exercised options and sold US$517k worth of stock

Nuvalent, Inc. Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

Nuvalent, Inc. Announces Promotion of Henry Pelish to Chief Scientific Officer

CFO & Treasurer notifies of intention to sell stock

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Independent Director notifies of intention to sell stock

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Chief Legal Officer & Secretary exercised options and sold US$528k worth of stock

Nuvalent, Inc. Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

Nuvalent, Inc., Annual General Meeting, Jun 12, 2024

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Price target increased by 10% to US$102

Independent Director notifies of intention to sell stock

Price target increased by 8.6% to US$92.13

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Price target increased by 7.4% to US$84.83

Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Chief Development Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

New minor risk - Share price stability

Price target increased by 11% to US$59.14

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with Ros1-Positive NSCLC and Other Solid Tumors

New major risk - Revenue and earnings growth

Price target increased by 8.7% to US$50.83

Chief Legal Officer & Secretary notifies of intention to sell stock

Price target increased by 8.7% to US$50.80

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Chief Development Officer exercised options and sold US$125k worth of stock

Price target increased by 10% to US$46.75

Chief Development Officer exercised options and sold US$113k worth of stock

Chief Development Officer exercised options and sold US$77k worth of stock

Chief Development Officer exercised options and sold US$86k worth of stock

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer exercised options and sold US$85k worth of stock

Chief Legal Officer & Secretary exercised options and sold US$51k worth of stock

Chief Development Officer exercised options and sold US$121k worth of stock

Nuvalent Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520

Chief Development Officer exercised options and sold US$130k worth of stock

Price target increased to US$43.67

High number of new directors

Chief Legal Officer & Secretary exercised options and sold US$287k worth of stock

Nuvalent, Inc. Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC

Chief Development Officer exercised options and sold US$85k worth of stock

Nuvalent, Inc. Currently Enrolling Patients in the Phase 1 Portion of Its Arros-1 Study, A Phase 1/2 Clinical Trial

Chief Development Officer exercised options and sold US$72k worth of stock

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation